Active Portfolio

Our investment portfolio includes companies passionate about the development and commercialization of innovative products and platform technologies for the prevention, diagnosis and treatment of significant diseases.

f-star GmbH

f-star is a biotherapeutics platform company developing next generation antibodies (Ab) and Ab fragments. Their core technology allows the introduction of antigen binding sites into non-CDR loops of Abs, enabling high affinity target binding by Fc fragments or the addition of new binding sites into full length Abs to create bi-specific molecules. f-star is located in Vienna, Austria and Cambridge, UK. MPH participated in f-star’s Extended Series A financing round in January 2010. For more information, please visit www.f-star.com.

FORGE Therapeutics

Forge Therapeutics is using a novel drug discovery platform to identify and develop first-in-class therapeutics against metalloprotein drug targets.
Their lead program is a non-hydroxamate inhibitor of LpxC, for the treatment of life-threatening gram negative bacterial infections. Forge is based in San Diego, CA. MPH participated in Forge's Series A financing round in April 2017. For more information, please visit www.forgetherapeutics.com. .

GenKyoTex

GenKyoTex is a leader in the development of novel therapeutics targeting Nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases, also called NOX enzymes. GenKyoTex has developed a unique screening platform to identify selective, first in class, novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. These include diabetes, cardiovascular, neurodegenerative and pulmonary diseases. The lead compound, GKT137831, is a selective NOX1/4 inhibitor that will enter Phase 1 trials later in 2011 and is targeted for the treatment of diabetic nephropathy. MPH participated in the Series C financing round in May 2011. For more information please visit www.genkyotex.com.

miRagen

miRagen Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need. Their lead program is a pro-miR for miR-29 in Phase 1 testing for fibrosis. miRagen has additional programs in cancer, cardiovascular disease and ALS. miRagen is based in Boulder, CO. MPH participated in miRagen's Series C financing round in November 2015. For more information, please visit www.miragenrx.com.

Pronota

Pronota NV is a Belgian diagnostics company with two cutting-edge technologies for low abundance protein biomarker discovery and antibody-free, multiple protein assay development. MPH participated in Pronota's Series B financing round in October 2009. Pronota merged with a division of Biocartis in September 2014 to form MyCartis. For more information, please visit www.mycartis.net.

QurAlis

QurAlis is a Boston-based biopharmaceutical company focused on the discovery and development of potential new therapeutics for ALS (Amyotrophic Lateral Sclerosis). For more information, please visit www.quralis.com.

Ribometrix

Ribometrix is a Durham, North Carolina based biotech company focused on developing small molecule therapeutics for RNA targets. Ribometrix uses the SHAPE-MaP and RING-MaP technologies initially invented and developed by its founders to determine the 3D structure of RNA molecules implicated in human disease, and to screen for small molecules that modulate these RNAs. MPH participated in Ribometrix's seed financing round in October 2017. For more information, please visit www.ribometrix.com.

Rigontec

Rigontec is a biopharmaceutical company targeting RIC-I for the immune-mediated treatment of cancer and viral diseases. MPH participated in Rigontec's Series A financing round in August 2015. Rigontec is based in Bonn, Germany. For more information, please visit www.rigontec.de.

Thrasos

Thrasos Therapeutics is a clinical-stage biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). MPH participated in Thrasos’ Series C financing round in October 2012. For more information, please visit www.thrasos.com.